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Abstract
Objective: To investigate the factors associated with clinical progression and good prognosis in patients with lower limb
osteoarthritis (OA).
Methods: Cohort study of 145 patients with OA in either knee, hip or both. Progression was defined as 1) new joint
prosthesis or 2) increase in WOMAC pain or function score during 6-years follow-up above pre-defined thresholds. Patients
without progression with decrease in WOMAC pain or function score lower than pre-defined thresholds were categorized as
good prognosis. Relative risks (RRs) for progression and good prognosis with 95% confidence interval (95% CI) were
calculated by comparing the highest tertile or category to the lowest tertile, for baseline determinants (age, sex, BMI,
WOMAC pain and function scores, pain on physical examination, total range of motion (tROM), osteophytes and joint space
narrowing (JSN) scores), and for worsening in WOMAC pain and function score in 1-year. Adjustments were performed for
age, sex, and BMI.
Results: Follow-up was completed by 117 patients (81%, median age 60 years, 84% female); 62 (53%) and 31 patients (26%)
showed progression and good prognosis, respectively. These following determinants were associated with progression:
pain on physical examination (RR 1.2 (1.0 to 1.5)); tROM (1.4 (1.1 to 1.6); worsening in WOMAC pain (1.9 (1.2 to 2.3));
worsening in WOMAC function (2.4 (1.7 to 2.6)); osteophytes 1.5 (1.0 to 1.8); and JSN scores (2.3 (1.5 to 2.7)). Worsening in
WOMAC pain (0.1 (0.1 to 0.8)) and function score (0.1 (0.1 to 0.7)), were negatively associated with good prognosis.
Conclusion: Worsening of self-reported pain and function in one year, limited tROM and higher osteophytes and JSN scores
were associated with clinical progression. Worsening in WOMAC pain and function score in 1- year were associated with
lower risk to have good prognosis. These findings help to inform patients with regard to their OA prognosis.
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Introduction
Osteoarthritis (OA) of the lower limbs accounts for problems in
performing lower extremities tasks such as walking and stair
climbing.[1] Some of the patients with lower limb OA show
progression of their OA with some progressing to total joint failure
needing joint replacement.[2] Knowing those who will progress is
important because it will improve patient information on the
prognosis of OA.
Several studies have investigated determinants of the progres-
sion of knee and hip OA [3]–[5] and several remarks could be
made on these studies. Firstly, none of the studies investigated knee
and hip together. Investigating knee and hip separately is easy to
understand but it does not reflect the clinical practice. In more
than 30% of knee OA patients, hip OA is present at the same time
[6] and up to 78% of patients have bilateral OA in knees or
hips.[7] Concomitant presence of OA in lower limb joints will
affect the experience of pain and influence disability in all lower
limb joints. Arguably, it is difficult for a patient to allocate
complaints to a particular knee or hip joint. The questionnaires
used in OA, such as Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) asked questions on daily life
activities such as climbing the stairs, where knee and hip joints are
simultaneously needed.[8] Secondly, in most studies, progression
was defined as joint deterioration on a radiograph while from the
patient’s perspective clinical progression is more important.[2], [9]
Thirdly, almost exclusively baseline determinants of progression
were investigated. However, OA patients are included in cohort
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changes in determinants over a short time period of interest as
prognostic factors on the long term.
Clinical progression is relevant for patients, but it is difficult to
define. Probably this is one of the reasons why data on clinical
progression are lacking compared to data on radiological
progression. At this moment, there is no consensus on how to
define clinical progression of knee and hip OA progression.[10],
[11] Obviously, total joint replacement should be considered as
OA disease progression. However, not all patients with worsening
of their OA will receive joint replacement because of factors such
as patient’s comorbidity and surgeon’s preference. Self-reported
pain or disability could be used to define clinical progression, yet at
present no standardized ‘cut-off’ for progression on self-reported
outcome measures exists.
To deal with the abovementioned issues, we propose in the
present study a composite outcome which combines total joint
replacement and increase in self-reported pain and function
during 6-years follow-up above a clinically relevant cut-off [8] as
clinical progression. We sought to identify determinants associated
with clinical progression and determinants associated with good
prognosis of lower limb OA (knee and hip OA together). We
assessed baseline determinants and determinants which were
measured repeatedly over time.
Materials and Methods
Study design and patient population
This study is part of the Genetic ARthrosis and Progression
(GARP) study, a cohort study aimed at identifying determi-
nants of OA susceptibility and progression.[12] In this cohort,
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were included. To be included, patient should have symptom-
atic OA at multiple joint sites in the hands or OA in two or
more of the following joint sites: hand, spine (cervical or
lumbar), knee, or hip. Patients were recruited from the
rheumatologic, orthopedic and general practice clinics around
Leiden, The Netherlands. Patients with secondary OA, familial
syndromes with a clear Mendelian inheritance, and a shortened
life expectancy (,1 yr) were excluded. Patients underwent
baseline assessment between August 2000 and March 2003 and
filled-in questionnaires one year after this baseline visit. From
April 2007 to June 2008 patients who consented for a follow-up
evaluation (mean follow-up 6.1 years (range 5.1–7.5 years) were
assessed.
To be eligible for the present study, patients needed to have
OA in either knee or hip, or both. Knee OA was defined
according to American College of Rheumatology (ACR) criteria
as pain or stiffness in the knee on most days of the prior month
and the presence of osteophytes in the tibiofemoral joints.[13]
Hip OA was also defined according to ACR criteria as pain or
stiffness in the groin and hip region on most days of prior month
together with femoral or acetabular osteophytes or joint space
narrowing on the radiograph.[14] There were 168 patients with
knee or hip OA in the GARP cohort. Of these patients, 23
patients with prosthesis at baseline were excluded leaving 145
patients eligible for the follow-up. Patients with prosthesis at
baseline were excluded because these patients could be
considered as already having progressive disease at baseline and
because having first prosthesis could influence the decision in
having another prosthesis (confounder). This study was approved
by the Medical Ethics Committee of the Leiden University
Medical Center. Written informed consents form were obtained
from all participants.
Clinical assessment
Demographic data at baseline were recorded using standardized
questionnaires. Self-reported pain (five items) and functional
limitations (17 items) were evaluated by using the Dutch version
of the WOMAC in 100 mm visual analogue scale format at
baseline, at 1-year and at 6-year follow-up. It considered both
knees and hips in the last 48 hours. Total scores on the pain and
function subscales range from 0–100, higher scores indicated
worse outcome.
Physical health at baseline was assessed with the summary
component scales for physical health (PCS) of the Dutch validated
Medical Outcomes Study Short Form-36 (SF-36) derived from
norm based data from the Dutch population (mean 50, standard
deviation (SD) 10). [15,16] Higher scores indicate better physical
health.
Physical examinations were performed at baseline. Pain on
passive movement of the knee and hip joint was assessed using the
modified articular index described by Doyle et al [17] (range 0 to
3; 0: no pain, 1: patient expressed tenderness, 2: patient expressed
tenderness and winced, 3: patient expressed tenderness, winced
and withdrew the joint). The total pain score ranged from 0 to 12.
Flexion and extension of the knee and flexion and endorotation of
the hip were measured using a goniometer and summed up as total
range of motion (tROM).
Radiographs
Radiographs of the knees (posterior-anterior (PA); weight-
bearing, non-fluoroscopic fixed-flexion protocol) and hips (PA;
weight-bearing) at baseline were taken by a single experienced
radiographer using a standard protocol with a fixed film focus
distance (1.30 m). These analogue films were digitized using a film
digitizer at a resolution corresponding to a pixel size of 100 mu.
Using the OARSI atlas [18], two readers (EY, JB) scored the
radiographs by consensus opinion. Osteophytes were graded 0 to 3
in the hip, on the medial and lateral femur and in the medial and
lateral tibia. Joint space narrowing (JSN) was graded 0 to 3 in the
hip, and in medial and lateral tibiofemoral compartments of the
knees. Total scores for osteophytes ranged from 0–24 in the knees
and 0–6 in the hips. Total scores for JSN ranged from 0–12 in the
knees and 0–6 in the hips. Intra-reader reproducibility based on 25
randomly selected pairs of radiographs was excellent, with intra-
class correlation coefficient (ICC) of 0.99 for osteophytes and 0.98
for JSN.
Definition of progression and good prognosis
Clinical progression was defined as: 1) the acquirement of joint
replacement during follow-up or 2) an increase in self-reported
(WOMAC) pain or function from baseline to 6-years follow-up
above the predefined MPCI (minimum perceptible clinical
improvement). The joint replacement should be due to OA and
not due to other forms of arthritis or trauma. MPCI was originally
developed as threshold value to define treatment response in OA.
The threshold values were 9.7 for WOMAC pain and 9.3 for
WOMAC function.[8]
These threshold values with negative sign, were used to define
good prognosis. Patients without progression who had decrease in
WOMAC pain or function score in 6-years lower than 29.7 or
29.3, respectively, were defined as having good prognosis.
Statistical analysis
Data were analyzed using PASW Statistics 17 (SPSS Inc.,
Chicago, Ill, USA). Mean changes (SD and 95% confidence
interval (95% CI)) for WOMAC pain and function, PCS and pain
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scores from follow-up scores. Mean changes of scores with the
95% CI that did not cross 0 was considered as significant. The self-
reported pain and function change scores of every patient were
plotted in cumulative probability plot.
Determinants of clinical progression were assessed using logistic
regression analysis. We assessed the following baseline determi-
nants age, sex, BMI, WOMAC pain and function scores, pain on
physical examination, total range of motion (tROM) and
radiographic scores. We also assessed the determinants worsening
in WOMAC pain and function score in 1-year.
The following baseline determinants were categorized in
tertiles: BMI, WOMAC pain and function, tROM, osteophytes,
and JSN. Also categorized in tertiles were worsening in
WOMAC pain and function in 1-year. Pain on physical
examination was categorized into presence or absence of pain.
In the logistic regression analysis, the odds ratios (ORs) were
calculated by using the lowest category or the lowest tertile as
reference except for tROM where the highest tertile was used
as reference. The ORs were transformed to risk ratio (RRs)
using the approximation formula of Zhang because ORs of
common outcomes in a fixed cohort are not a good
approximation of RRs.[19] Since the population of this study
consists of sib pairs, intrafamily effect were taken into account
by computing robust standard errors using Stata version 8
(Stata, College Station, Tx, USA). In the analyses, adjustments
were made for age, sex, and BMI. A significant determinant of
progression was defined as a determinant that the 95% CI of its
RR did not cross 1.
The significant determinants were included in a multivariate
model to investigate whether these determinants could indepen-
dently predict the clinical progression. To get an impression on
how good these determinants predict clinical progression when
they presented together, the R
2 of this model was determined.
Additionally, to investigate the discriminative ability of the
multivariate model, we fitted a receiver operating characteristics
curve (ROC) and calculated the area under the curve (AUC). We
compared the predicted risk of progression with the observed
clinical progression and good prognosis with the observed clinical
progression and good prognosis.
Results
Population description
Of 145 patients eligible for the follow-up, 117 (81%) gave
consent for follow-up assessment. The reasons for non-consent
were: no interest in the follow-up study (n=8), unavailability of
transport (n=8) health problems not associated with OA (n=4),
emigration (n=1), and unknown (n=2). Five patients died during
follow-up.
Baseline characteristics of patients with and without follow-up
and excluded patients due to joint prosthesis at baseline are
presented in Table 1. No difference was found between baseline
characteristics of patients with and without follow-up (Table 1).
Clinical course of lower limb osteoarthritis
The mean changes (95%CI) of self-reported (WOMAC) pain
and function scores of all patients were 22.6 (28.9 to 3.7) and 0.5
(25.9 to 6.9), respectively (Table 2).
During follow-up, 36 patients (31%) received at least one joint
replacement; 15 for the hip, 16 for the knee, and five for both knee
and hip. In these patients with new joint replacements, the mean
WOMAC pain score (95% CI) decreased over the six years of
follow-up (28.5 (217.8 to 20.1). In the patients without new
prosthesis (n=81), WOMAC pain and WOMAC function scores
did not change significantly over time: 20.1 (28.3 to 8.1) and 1.9
(26.3 to 10.1), respectively.
Cumulative probability plots show the variation in natural
course of self-reported pain and function in the sub-group of
patients without prosthesis (n=81) (Figures 1a and 1b). Fifteen and
22 patients showed progression of WOMAC pain and WOMAC
function based on changes above the MCPI, respectively. In total,
26 patients (19.7%) showed clinical deterioration. Together with
the 36 patients receiving joint replacement during follow-up, 62 of
117 patients (53.0%) showed clinical progression. Thirty-one
patients showed good prognosis, based on change in WOMAC
pain or WOMAC function score change lower than 29.7 (n=23)
or 29.3 (n=22), respectively.
In the total study sample, in the subgroup of patients with new
prosthesis, and in patients without new prosthesis, physical health
summary measures using SF-36 did not change during follow-up
(Table 2). Compared to the general population (mean of 50 with
SD of 10), physical health of lower limb OA patients was
consistently shown to be worse at baseline and follow-up.
Pain during physical examination was worsened in the total
population (Table 2). In the sub-group with new prosthesis, pain
did not worsen.
Determinants of clinical progression of lower limb
osteoarthritis
Determinants of clinical progression of lower limb OA are
shown in Table 3. Age, female sex, and BMI, were not associated
with clinical progression. Worsening of WOMAC pain and
function scores in the first year were associated with 6-year
progression while WOMAC pain and function score at baseline
were not. Subjects in the highest tertile of WOMAC pain and
function worsening in 1 year had a RR (95% CI) of 1.9 (1.2 to 2.3)
and 2.4 (1.7 to 2.7), respectively, for clinical progression. The
presence of pain on physical examination at baseline was
associated with clinical progression (1.2 (1.0 to 1.5)). Patients in
the lowest tertile of tROM had a higher risk for clinical
progression RRs of 1.4 (1.1 to 1.6)). Osteophytes and JSN at
baseline were associated with clinical progression, RR for being in
the highest tertile of osteophytes and JSN scores were 1.5 (1.0 to
1.8) and 2.3 (1.5 to 2.6), respectively. In a multivariate regression
model, WOMAC function worsening in 1 year, limited t ROM,
and JSN scores were found as independent determinants of clinical
progression (Table 3). With these variables, explained variance
(R
2) was 48.6%. The AUCs of the ROC curves were 0.85 (95% CI
0.76 to 0.94).
Determinants of good prognosis of lower limb
osteoarthritis
Worsening in WOMAC pain and function score in 1 year were
negatively associated with good prognosis, i.e. patients in highest
tertile of 1-year increase in WOMAC pain and function scores
had lower risk to have good prognosis. (Table 4). Patients in the
highest tertile of worsening of WOMAC pain and function in 1
year, had RR of 0.1 (95% CI 0.1 to 0.8) and 0.1 (0.1 to 0.7),
respectively to have good prognosis of their lower limb OA
compared to patients with WOMAC pain and function change in
the lowest tertile. When these significant determinants were
analyzed in one model, only worsening in WOMAC function in
1- year was negatively associated with good prognosis. The R
2 of
this model was 43.3% and the AUCs of the ROC curves were
0.78 (0.68 to 0.89).
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Follow-up (n=117) No follow-up (n=28) Joint prosthesis at baseline (n=23)
Age, yrs, median (IQR)
60 (55–66) 62 (53–58) 64 (61–68)
Female, no (%)
98 (84) 24 (74) 13 (72)
BMI, kg/m
2, mean (range)
28.0 (20 to 47) 27.3 (20 to 38) 29.3 (22 to 43)
Patients with OA, no (%)
Knee 74 (63) 18 (55) 3 (17)
Hip 31 (27) 6 (18) 6 (33)
Knee and hip 11 (10) 9 (27) 9 (50)
Total range of
motion, u, mean (range)
258 (133 to 389) 257 (219 to 441) 251 (48 to 360)
Knee flexion 86 (1 to 155) 86 (0 to 155) 85 (16 to 135)
Knee extension. 24( 230 to 10) 23( 230 to 16) 22( 215 to 16)
Hip flexion 134 (100 to 176) 134 (8 to 166) 133 (8 to 175)





Knee and hip 1
Presence of pain on
physical examination, no (%)*
85 (73) 20 (71) 17 (74)
Hip 30 (26) 9 (32) 14 (61)
Knee 64 (55) 16 (57) 11 (48)
*Patients may have OA at multiple joints at one time and can have pain in the knee and hip joint simultaneously. Abbreviation: IQR: interquartile range; BMI: Body Mass
Index.
doi:10.1371/journal.pone.0025426.t001
Table 2. Mean (standard deviation (SD)) baseline, follow-up (FU), and change scores on self-reported pain and function (WOMAC),
physical health (PCS), and pain on physical examination (PE) for the total population and sub-groups.
Baseline Follow-up Change (95% CI)
All patients (n=117) WOMAC pain 36.2 (23.5) 33.6 (25.7) 22.6 (28.9 to 3.7)
WOMAC function 33.1 (24.3) 33.6 (24.8) 0.5 (25.9 to 6.9)
PCS 41.8 (9.8){ 42.0 (10.1){ 0.2 (22.4 to 2.8)
Pain on PE 1.7 (1.7) 2.4 (2.4) 0.7 (0.2 to 1.2){
Patients receiving prosthesis
during FU (n=36)
WOMAC pain 36.5 (18.2) 28.0 (21.0) 28.5 (217.8 to20.1){
WOMAC function 32.4 (20.1) 30.0 (20.6) 22.4 (212.0 to 7.2)
PCS 40.8 (9.1){ 40.7 (10.0){ 20.1 (24.6 to 4.4)
Pain on PE 1.8 (1.6) 2.8 (3.1) 1.0 (20.2 to 2.2)
Patient not receiving prosthesis
during FU (n=81)
WOMAC pain 36.1 (25.6) 36.0 (27.2) 20.1 (28.3 to 8.1)
WOMAC function 33.4 (26.1) 35.3 (26.4) 1.9 (26.3 to 10.1)
PCS 42.3 (10.1){ 42.6 (10.0){ 0.3 (22.8 to 3.4)
Pain on PE 1.7 (1.8) 2.3 (2.1) 0.6 (20.01 to 1.2)
{: statistically significant; the significance of physical health summary were tested by comparing the study sample with the norm based population (mean=50, SD=10).
doi:10.1371/journal.pone.0025426.t002
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To our knowledge, the present study is the first which
investigated determinants of clinical progression of knee and hip
together. Clinical outcome is chosen because it is essential to
patients. Clinical progression was present in 53% of patients; 33%
by receiving joint prosthesis and 20% by deteriorating of self-
reported pain or function.
Self-reported pain improved over 6 years in patients who
received prostheses. Self-reported function did not change over 6
years regardless of joint replacement. The combination of
WOMAC function changes in 1 year, limited tROM, and JSN
scores provided the best explanation of variation in clinical
progression of lower limb OA. Worsening WOMAC pain and
function in 1 year were negatively associated with good prognosis.
Patients in the highest tertile of worsening in WOMAC pain and
WOMAC function in 1-year had 90% less chance to have good
prognosis of their lower limb OA compared to patients with pain
and function change in the lowest tertile.
The proportion of the study sample showing clinical progres-
sion in our study is comparable to results from the Bristol ‘OA
500 study’. In that descriptive study, where the majority of the
study population was also female, clinical change was reported by
the patients as: better, same, and worse. They found that 63%
and 54% of the patients reported worsening in overall condition
for the knee and hip respectively, after 8 years follow-up.[9] In
Figure 1. Cumulative probability plot of Western Ontario and McMaster Universities (WOMAC) scores change of patients without
prosthesis during follow-up (n=81) for WOMAC pain scores change (above) and WOMAC function scores change (below). The
horizontal line above is the line set at minimal perceptible clinical improvement (MPCI) score which is used as the cut-off to define progression and
the horizontal line below is the line set to define good prognosis.
doi:10.1371/journal.pone.0025426.g001
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group did not change in 6 years. This can be explained by the
variation in progression between individuals as depicted in the
cumulative probability plots (Figure 1a and 1b). Although some
patients remained stable and even reported improvement, a
considerable proportion of patients reported more pain and
worse function. As a result the mean change is small. As expected
in the sub-group of patients receiving joint prosthesis during
follow-up, self-reported pain improved over 6 years, however,
self-reported function did not. These results are consistent with
the notion that joint replacement is an effective treatment for
pain in lower limb OA. However, it seems that joint replacement
cannot replace the function of the natural joint. Our results
showed some parallels with a recent study by Nilsdotter et al.[20]
They showed that patients had high preoperative expectations
concerning reduction of pain and function but one year after
knee replacement only the expectation regarding reduction of
pain was fulfilled.
Table 3. Determinants for clinical progression over 6 years of lower limb osteoarthritis.
Determinant Number of patients Risk ratio (95% CI)






Age.60 years 59 (50) 50 (43) 1.0 (0.9 to 1.1) na
Female sex 48 (41) 50 (43) 0.6 (0.3 to 1.0) na
Body mass index (kg/m
2)
,25.5 19 (16) 20 (17) 1 na
25.5 to 29.1 16 (14) 21 (18) 0.9 (0.5 to 1.2)
.29.1 27 (23) 14 (12) 1.3 (0.9 to 1.7)
WOMAC pain scores
0 to 23.2 21 (18) 18 (15) 1 na
23.2 to 45.9 20 (17) 18 (15) 0.9 (0.5 to 1.3)
.45.9 21 (18) 19 (16) 1.1 (0.7 to 1.4)
WOMAC function scores
0 to 18.0 20 (17) 20 (17) 1 na
18.0 to 40.9 22 (19) 16 (14) 1.2 (0.7 to 1.6)
.40.9 20 (17) 19 (16) 1.1 (0.7 to 1.5)
Change in WOMAC pain score in 1 year
,23.3 10 (9) 16 (14) 1 na
23.3 to 10.1 15 (13) 11 (9) 1.6 (0.8 to 2.2)
.10.1 17 (15) 9 (8) 1.9 (1.2 to 2.3){
Change in WOMAC function score in 1 year
,21.4 9 (8) 17 (15) 1 1
21.4 to 6.7 13 (11) 14 (12) 1.5 (0.9 to 2.7) 1.9 (0.9 to 2.6)
.6.7 20 (17) 5 (4) 2.4 (1.7 to 2.7){ 2.3 (1.2 to 2.8){
Pain on physical examination 44 (38) 13 (11) 1.2 (1.0 to 1.5){ 1.2 (0.8 to 1.2)
Total range of motion (u)
.554 14 (12) 25 (21) 1 1
522 to 554 25 (21) 14 (12) 1.4 (1.01 to 1.7) 1.2 (0.9 to 1.2)
,522 23 (20) 16 (14) 1.4 (1.1 to 1.6){ 1.2 (1.03 to 1.3){
Osteophyte scores
1 19 (16) 28 (24) 1 na
2 to 4 19 (16) 10 (9) 1.4 (1.0 to 3.8){
.4 11 (9) 8 (7) 1.5 (1.0 to 1.8){
JSN scores
1 19 (16) 32 (27) 1 1
2 to 4 16 (14) 12 (10) 1.5 (0.9 to 2.1) 1.6 (0.7 to 2.4)
.4 14 (12) 2 (2) 2.3 (1.5 to 2.6){ 2.4 (1.9 to 2.7){
1except for determinants age, sex and BMI themselves, adjustment was made for age, sex and BMI.
2multivariate model using a backward selection (R
2=48.6%). The independent variables with univariate associations with a p-value #0.10 were included.
Both models are calculated using approximation formula of Zhang.[19].
{: statistically significant.
Abbreviations: WOMAC: Western Ontario and McMaster Universities, JSN: joint space narrowing, na: not applicable.
doi:10.1371/journal.pone.0025426.t003
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clinical progression, rapid deterioration in self-reported pain
and function in the first year (even after correction for WOMAC
scores at baseline that could confound the association) was
associated with higher risk of progression over 6 years. This has
not been studied before in OA, but it is in accordance with
studies in rheumatoid arthritis (RA): worsening in self-reported
disability measured with the health assessment questionnaire
was a predictor for severe RA outcomes on the long term.[21]
Interestingly, worsening in WOMAC pain and function score in
1-year were negatively associated with good prognosis. The
consequence of these findings is that by following lower limb
OA patients for 1 year, doctors can inform the patients about
the progression of the OA in the long term. Therefore, it might
advisable that doctors see their patients again 1-year after the
first visit. It will be also interesting to investigate in a clinical
trial whether modification of self reported pain or function one
year after the presentation by means of physical therapy or
Table 4. Determinants of good prognosis of lower limb osteoarthritis over 6 years.
Determinant Number of patients Risk ratio (95% CI)






Age.60 years 28 (24) 3 (3) 1.0 (0.7 to 1.0) na
Female sex 29 (25) 68 (58) 2.8 (0.8 to 6.3) na
Body mass index (kg/m
2)
,25.5 14 (12) 25 (21) 1 na
25.5 to 29.1 12 (10) 25 (21) 0.9 (0.4 to 1.6)
.29.1 5 (4) 35 (30) 0.3 (0.1 to 0.9)
WOMAC pain scores
0 to 18.0 4 (4) 34 (29) 1 na
18.0 to 45.9 14 (12) 24 (20) 2.7 (0.7 to 3.6)
.40.9 13 (11) 27 (23) 2.2 (0.7 to 3.8)
WOMAC function scores
0 to 18.0 6 (5) 34 (29) 1 na
18.0 to 40.9 13 (11) 24 (20) 2.5 (0.1 to 4.5)
.40.9 12 (10) 27 (23) 1.9 (0.7 to 3.8)
Change in WOMAC pain score in 1 year
,23.3 14 (12) 12 (10) 1 na
23.3 to 10.1 5 (4) 21 (18) 0.3 (0.1 to 0.6){ 0.6 (0.1 to 1.3)
.10.1 3 (3) 23 (20) 0.1 (0.1 to 0.8){ 0.5 (0.1 to 1.1)
Change in WOMAC function score in 1 year
,21.4 15 (13) 11 (9) 1 1
21.4 to 6.7 5 (4) 22 (19) 0.3 (0.1 to 0.7){ 0.3 (0.1 to 0.8){
.6.7 2 (2) 23 (18) 0.1 (0.1 to 0.7){ 0.2 (0.1 to 0.8){
Pain on physical examination 20 (17) 11 (9) 0.9 (0.6 to 1.1) na
Total range of motion (u)
.554 12 (10) 27 (23) 1 na
522 to 554 10 (9) 28 (24) 0.8 (0.3 to 1.7)
,522 9 (8) 30 (26) 0.9 (0.4 to 1.8)
Osteophyte scores
1 17 (15) 30 (26) 1 na
2 to 4 6 (5) 23 (20) 0.6 (0.2 to 1.2)
.4 4 (3) 15 (13) 0.5 (0.2 to 1.3)
JSN scores
1 18 (15) 33 (28) 1 na
2 to 4 7 (6) 21 (18) 0.7 (0.3 to 1.4)
.4 2 (2) 14 (12) 0.4 (0.1 to 1.4)
1except for determinants age, sex and BMI themselves, adjustment was made for age, sex and BMI.
2multivariate model using a backward selection (R
2=43.3%). The independent variables with univariate associations with a p-value #0.10 were included.
Both models are calculated using approximation formula of Zhang.[19].
{: statistically significant.
Abbreviations: WOMAC: Western Ontario and McMaster Universities, JSN: joint space narrowing, na: not applicable.
doi:10.1371/journal.pone.0025426.t004
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OA.
Pain on physical examination at baseline was associated with
clinical progression. It was also the only pain variable that
deteriorated over time. This observation reflects that pain as
reported by the patient differs from pain on passive movement as
found during physical examination as shown previously.[22]
Limited tROM (RR 1.4, 95%CI 1.1 to 1.6) and presence of
pain on physical examination at baseline (RR 1.2, 95%CI 1.0 to
1.5) probably reflected the structural damage and might be used as
a surrogate for osteophyte and JSN scores. In a recent EULAR
recommendation for the diagnosis of knee OA, limited movement
was indeed proposed as one of the clinical signs needed to make
the diagnosis, probably because it was associated with radiological
OA.[23]
Osteophytes and JSN scores were also identified as determinants
of lower limb OA progression. Our findings support the findings of
Lane and colleague, that osteophyte, JSN together with subchon-
dral bone sclerosis were associated with hip OA progression.[4]
We showed that the WOMAC function changes in 1 year,
limited tROM and higher JSN scores were independently
significant determinants of clinical progression of lower limb
OA. Although the main aim of this paper was to identify the
determinants that were associated with clinical progression and
not to build a prognostic model, we tried to get an impression on
how good these determinants in predicting clinical progression
when they were present together. We also tested the discriminative
ability of this model to get an indication on how good the presence
of these determinants predicts the clinical progression of lower
OA. Their cumulative presence provided a very good explanation
of variation in clinical progression, as shown with R
2 of 48.6%.
The AUCs of the ROC curves of 0.80 also indicates a reasonable
discriminative ability. This means that performing assessment on
these three determinants in clinical practice will help clinician
much in predicting the progression of lower limb OA and
therefore give better patient information.
Roos et al showed that female sex was associated with
worsening in self-reported pain and function and that older age
and higher BMI were associated with worsening in function
assessed on physical examination. On the other hand, we found no
associations between demographic determinants and clinical
progression.[5] Determinants for incidence are often failed to be
identified as determinant of progression. The failure in finding
determinants for progression is a common phenomenon that
might be caused by methodological problem in studies restricted to
subjects with existing disease.[24] Unfortunately, no method is yet
available to overcome this problem. Another possible explanation
in the difference in our results and results from Roos et al is the
difference in patient population. The population in the study of
Roos was a mix of knee OA patients and participants who
underwent menisectomy in the past.
Our study sample that consists of selected sib-pairs with OA at
multiple sites has strengths and limitations. Since generalized OA
(GOA) population is associated with rapid OA progression [25],
our study population is suitable to investigate OA progression
within a relatively short period. However, the generalizability of
our results in other population settings, especially to general
practice clinics is arguably limited and we could not investigate
GOA as determinant for progression. Yet, if we compare the
‘severity of OA’ by taking the incidence of joint prosthesis, we did
not see much difference in the incidence of joint prosthesis in our
study sample and in a hospital based OA population which was
not selected for GOA, for a comparable follow-up time.[9] It
supports the observations in other patient populations that
generalized OA is also common and it is important to bear in
mind that OA is often present at multiple sites while only the most
symptomatic sites draw attention.[9], [25] To leave out the
familial effect, we have performed a correction for familial factors
in analysis.
The choice of the composite outcome that is a combination of
two outcomes: joint prosthesis and increase in WOMAC pain or
function scores above MPCI rewards comments. The two
outcomes might be different; increase in WOMAC scores above
MPCI might not always results in joint prosthesis. Also, the use of
MPCI in defining progression is arbitrary. It was originally created
to indicate clinical improvement in trials.[8] However, since no
clinical outcome regarding clinical progression of knee or hip or
lower limb OA is available at this moment, our choice of outcome
could be considered to be used in observational studies.
It should be noted that our study population consists mainly of
female. OA is known to be more common in female. The
phenomenon that female tend to be overrepresented in OA studies
is well known, such as in the large Bristol ‘OA 500 study’
mentioned above.[9] In the present study, effort has been taken to
adjust for this possible confounder.
In summary, over a period of 6 years, more than half of the
patients showed progression of lower limb OA, based on total joint
replacement or change in self-reported pain or function above the
MPCI. Performing combination of clinical and radiological
assessment in clinical practice could evaluate the sub-group of
patients with progression of lower limb OA. These findings would
help doctors in patient information regarding progression of lower
limb OA.
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